Xyone Therapeutics Inc.
Clinical-stage biotechnology company developing first-in-class therapeutics for immuno-oncology (MUC1-C targeting) and diagnostic and formulation solutions for endocrine disorders (accurate free testosterone measurement and sustained-release hormone formulations). Engages in translational research with academic and clinical partners and publishes peer-reviewed scientific work.
Industries
N/A
Nr. of Employees
small (1-50)
Xyone Therapeutics Inc.
Patents
Products
MUC1-C‑targeted therapeutic candidates
Preclinical and clinical-stage therapeutic agents that target the MUC1-C oncoprotein for treatment of diverse human carcinomas and select hematologic malignancies.
Algorithmic companion diagnostic for free testosterone
A diagnostic framework that implements a non‑linear/allosteric model of testosterone binding to improve accuracy of free testosterone estimation versus traditional computed methods.
Nano/microparticle sustained‑release hormone formulation (nTc candidate)
Aqueous nanoparticle/microparticle formulation for testosterone intended to provide programmable, sustained and uniform release over prolonged periods to improve pharmacokinetics and adherence.
MUC1-C‑targeted therapeutic candidates
Preclinical and clinical-stage therapeutic agents that target the MUC1-C oncoprotein for treatment of diverse human carcinomas and select hematologic malignancies.
Algorithmic companion diagnostic for free testosterone
A diagnostic framework that implements a non‑linear/allosteric model of testosterone binding to improve accuracy of free testosterone estimation versus traditional computed methods.
Nano/microparticle sustained‑release hormone formulation (nTc candidate)
Aqueous nanoparticle/microparticle formulation for testosterone intended to provide programmable, sustained and uniform release over prolonged periods to improve pharmacokinetics and adherence.
Services
Collaborative preclinical and translational research engagements with academic medical centers and clinical partners to advance therapeutic and diagnostic candidates.
Collaborative preclinical and translational research engagements with academic medical centers and clinical partners to advance therapeutic and diagnostic candidates.
Expertise Areas
- Immuno-oncology therapeutic development
- Endocrine diagnostics and assay development
- Sustained‑release formulation development for hormones
- Computational modeling and bioinformatics for diagnostics
Key Technologies
- Nanoparticle/microparticle sustained‑release formulations
- Biodegradable polymer formulations (PLGA, PLA and copolymers)
- Computational algorithms for hormone–binding models
- Biophysical binding assays and equilibrium dialysis
News & Updates
Announcement of two NIA/SBIR grants totaling over $2.5M to advance studies in androgen dysregulation.
Congratulatory note regarding the start of a Phase 1 study of an allogeneic CAR‑T cell product targeting MUC1-C by an external company.
Awarded two NIA/SBIR grants totaling over $2.5M to support androgen dysregulation research.
Announcement of two NIA/SBIR grants totaling over $2.5M to advance studies in androgen dysregulation.
Congratulatory note regarding the start of a Phase 1 study of an allogeneic CAR‑T cell product targeting MUC1-C by an external company.
Awarded two NIA/SBIR grants totaling over $2.5M to support androgen dysregulation research.